Cancer Glycobiomarkers Facing Precision Oncology
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 6730
Special Issue Editors
Interests: glycobiology; cancer; congenital disorders of glycosylation; cancer immunotherapy; antibodies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Glycosylation is a highly dynamic and controlled event resulting from the concerted action of glycosyltransferases, glycosidases, and substrates. Glycans, alone or in the form of glycoconjugates (glycoproteins, proteoglycans, glycolipids), are relevant components of the cells and directly contribute to several biological events.
It is well established that glycan diversity is much higher than other biological molecules. This so-called glycocode changes dramatically with malignant transformation and evolves with disease progression and dissemination, impacting all cancer hallmarks. Namely, abnormal glycosylation alters cancer cell signaling, modulating proliferation, migration, and invasion. Glycans also mediate tumor recognition by immune cells through interaction with glycan binding lectins and other receptors, playing a key role in immune evasion in cancer. Thus, understanding cancer glycobiology is a prerequisite to understanding cancer biology.
Over the past decade, high throughput analytical tools have been used to comprehensively interrogate the glycome and glycoproteome of cancer cells, providing a better understanding of their role in health and disease. Some glycoforms have shown tremendous potential for precision oncology, improving early diagnosis, prognosis, risk stratification, and providing markers of treatment response. This has fostered advances in cancer detection tools, stratification models, novel targeted therapies, and immunotherapy, including glycoconjugate vaccines and CAR-Ts.
This Special Issue welcomes works that may further contribute to this rationale, exploring cancer-associated glycans and glycoconjugates in the context of precision oncology, namely non-invasive cancer detection, diagnosis, patient stratification, response to treatment, and innovative therapeutics.
Prof. Paula A. Videira
Dr. José Alexandre Ferreira
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
